Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$7.5M
4M shares
52-week range
$1.70 – $11.19
1% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $500.0K | $500.0K | $500.0K | $500.0K | $500.0K | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $500.0K | $500.0K | $500.0K | $500.0K | $500.0K | $0 | $0 | $0 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — |
| R&D | $11.9M | $13.1M | $11.3M | $10.6M | $11.7M | $11.3M | $11.6M | $7.8M |
| Operating income | −$21.1M | −$20.6M | −$18.5M | −$21.0M | −$24.9M | −$21.0M | −$19.1M | −$14.7M |
| EBITDA | −$21.2M | −$16.6M | −$21.3M | −$20.9M | −$31.7M | −$19.9M | −$17.9M | −$13.8M |
| Net income | −$11.9M | −$16.9M | −$21.5M | −$20.8M | −$35.9M | −$19.5M | −$18.6M | −$14.5M |
| Net margin | -2376.7% | -3370.3% | -4296.7% | -4153.9% | -7179.6% | — | — | — |
| EPS (diluted) | -132.23 | -151.01 | -131.51 | -748.77 | -65.55 | -28.14 | -21.10 | -6.83 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $4M | $-3.28 | $-3.93–$-2.85 | 2 |
| 2027 | $5M | $-2.15 | $-2.77–$-1.78 | 3 |
| 2028 | $12M | $-1.94 | $-2.70–$-1.46 | 3 |
| 2029 | $11M | $-2.03 | $-2.03–$-2.03 | 1 |
Forward consensus · source: Financial Modeling Prep
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.
www.imunon.comNo one on the platform currently holds IMNN.
No tracked institution reports a position in IMNN as of their last filing.
| Execution date | Ratio |
|---|---|
| 2025-08-07 | 1.15-for-1 |
| 2025-07-25 | 1-for-15reverse |
| 2022-03-01 | 1-for-15reverse |
| 2017-05-30 | 1-for-14reverse |
| 2013-10-29 | 1-for-4.5reverse |
No one on the platform has traded IMNN yet.
| $8M |
| — |
| COCPCocrystal Pharma, Inc. | $1.02 | +0.99% | $10M | — |
| DWTXDogwood Therapeutics, Inc. | $1.65 | +11.49% | $3M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$IMNN I asked my own brain, because I possess both critical and analytic thinking skills, to document the evolution of celsion boilerplate fake drug promotion and dilution scam activity and there was no change detected. This is exactly the same as butter coated doxorubicin 1.9, 2.0, 3.0. Same management. Same press releases. Same financing sources. Same mindless retail bots who do no research.
View on StockTwits ↗$IMNN how did we end up in this situation
View on StockTwits ↗$IMNN Unbelievable: it looks like a day of miracles; the stock is up 7% today, yet it’s trading at 1.80—meaning 0.12 [pre-split]... to get back to at least the pre-reverse-split price, it would need to rise 300%—something that might happen around "Christmas in August"!!! They are desperate!!!! That’s the truth!!! They are losing their jobs!! That is the truth!! After spending 40 years creating nothing, failing at everything, and telling lies—what other job do you think Tordugno could get in America? And Stacy Lindborg? They have lost all credibility... the stock has hit rock bottom.
View on StockTwits ↗So, I asked ChatGPT for evolution in $IMNN management's partnership language over the past year: The rhetoric has clearly evolved from "we're looking for financing" to confirming active discussions with multiple companies. Not proof of an imminent deal, BUT this is the strongest partnership language Imunon has used publicly to date.
View on StockTwits ↗$IMNN Unfortunately I have to agree with jegglie here, the CEO has been touting partnership etc for over a year with only a 90% stock decline and nothing to show for all the talk.
View on StockTwits ↗$IMNN Celsion is a flea. A rounding error. Nobody is negotiating for their property. Any legitimate drug company that wants, it will simply just take it away for $8 million.
View on StockTwits ↗$IMNN on Life Sciences Investor Forum on June 25 says (transcript): ☆ WE DO HAVE ONGOING DISCUSSIONS... ☆ AS INFORMATION REQUESTS COME IN ☆ I THINK IT'S SOMETHING WE HAVE AN OPPORTUNITY TO GIVE UPDATE ☆ WILL CONTINUE WITH BIGGER PHARMA ( ˘▽˘)っ♨
View on StockTwits ↗$IMNN Valuation is not just about how many years to go in Phase 3, but the years and accumulated capital it takes to get to this point. If P3 succeeds this is a multi-billion dollar entity, but if any kind of data come out prior, or just enrollment progressing, partnerships or an outright acquisition are also on the cards. I do expect a hundred million valuation during P3, just don't know when it will happen.
View on StockTwits ↗$IMNN I'm sure bears will find a way to spin the iDMC review as bad. Sell, sell, sell!
View on StockTwits ↗$IMNN they just need to get through the next 3 quarters, then it’s 🎇
View on StockTwits ↗$IMNN and coming just before the life sciences investor forum could be a greaet way to see this ticker going up now!
View on StockTwits ↗$IMNN this is a great news to me! https://investors.imunon.com/news-releases/news-release-details/imunon-announces-data-monitoring-committee-recommends
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.